BZDS1901 manufacturing agreement

AdAlta executes first Australian manufacturing work order for BZDS1901 CAR-T therapy

BZDS1901 is a first in class CAR-T therapy targeting mesothelioma, with enourgaing early clinical data reported from studies conducted in China

• AdAlta and Cell Therapies sign first work order to bring first in class CAR-T cell therapy BZDS1901 to Australia

• BZDS1901 shows potential to offer new hope for advanced mesothelioma patients, with complete tumor clearance observed in some patients after two prior treatments with chemotherapy and immunotherapy (including one patient where tumours have still not returned 22 months after treatment)

• Establishment of an Australian manufacturing process is a key requirement to support planned Phase 1 clinical trials

• Manufacturing optimisation and transferability are important components of AdAlta’s partnering strategy

• BZDS1901 targets an estimated US$4.2 billion segment of the advanced mesothelioma market, with the total mesothelioma market forecast to reach US$12.2 billion by 2034

AdAlta CEO, Dr Tim Oldham said:

“Having a robust, well controlled and scalable manufacturing process for patient specific CAR-T cell therapies such as BZSD1901 is not just essential to enable further clinical studies, it is a major value inflection point in its own right because of the criticality of CAR-T manufacturing to larger biopharma companies who will ultimately license or acquire BZDS1901. We are delighted to be working with CTPL, one of the best manufacturers in the business, to ensure we have a global manufacturing reference site for BZDS1901 as we advance towards clinical trials in Australia.”